全文获取类型
收费全文 | 648篇 |
免费 | 27篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 27篇 |
妇产科学 | 3篇 |
基础医学 | 33篇 |
口腔科学 | 4篇 |
临床医学 | 32篇 |
内科学 | 384篇 |
皮肤病学 | 5篇 |
神经病学 | 30篇 |
特种医学 | 46篇 |
外科学 | 12篇 |
综合类 | 4篇 |
预防医学 | 62篇 |
眼科学 | 1篇 |
药学 | 12篇 |
中国医学 | 4篇 |
肿瘤学 | 18篇 |
出版年
2021年 | 5篇 |
2019年 | 5篇 |
2018年 | 7篇 |
2016年 | 4篇 |
2015年 | 6篇 |
2014年 | 16篇 |
2013年 | 18篇 |
2012年 | 31篇 |
2011年 | 35篇 |
2010年 | 25篇 |
2009年 | 26篇 |
2008年 | 23篇 |
2007年 | 39篇 |
2006年 | 34篇 |
2005年 | 35篇 |
2004年 | 39篇 |
2003年 | 39篇 |
2002年 | 31篇 |
2001年 | 28篇 |
2000年 | 35篇 |
1999年 | 17篇 |
1998年 | 10篇 |
1997年 | 10篇 |
1996年 | 16篇 |
1995年 | 15篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 3篇 |
1985年 | 6篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1972年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有677条查询结果,搜索用时 31 毫秒
1.
2.
3.
Snyder DS; Negrin RS; O'Donnell MR; Chao NJ; Amylon MD; Long GD; Nademanee AP; Stein AS; Parker PM; Smith EP 《Blood》1994,84(5):1672-1679
Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation (BMT). The median time from diagnosis to BMT was 7.0 months (range, 2.3 to 72.0 months). Sixty patients were treated before BMT with hydroxyurea alone, four patients with busulfan alone, one patient with interferon alone, and the other 29 patients were treated with various combinations of these drugs. Cumulative probabilities of overall survival, event- free survival, and relapse at 5 years were 73%, 64%, and 14%, respectively. The median follow-up time for surviving patients was 38 months, ranging from 12 to 88 months. By stepwise Cox regression analysis, significant prognostic variables were age at transplant, acute graft-versus-host disease > or = grade II, cytomegalovirus- associated interstitial pneumonitis, and years from diagnosis to BMT. 相似文献
4.
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables 总被引:9,自引:0,他引:9
Dangas G Iakovou I Nikolsky E Aymong ED Mintz GS Kipshidze NN Lansky AJ Moussa I Stone GW Moses JW Leon MB Mehran R 《The American journal of cardiology》2005,95(1):13-19
We previously found that contrast-induced nephropathy (CIN) complicating percutaneous coronary intervention adversely affects patients with chronic kidney disease (CKD). Therefore, we further investigated whether the predictors and outcome of CIN after percutaneous coronary intervention differ among patients with versus without CKD. Among 7,230 consecutive patients, CIN (>or=25% or >or=0.5 mg/dl increase in preprocedure serum creatinine 48 hours after the procedure) developed in 381 of 1,980 patients (19.2%) with baseline CKD (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2)) and in 688 of 5,250 patients (13.1%) without CKD. Decreased eGFRs, periprocedural hypotension, higher contrast media volumes, lower baseline hematocrit, diabetes, pulmonary edema at presentation, intra-aortic balloon pump use, and ejection fraction <40% were the most significant predictors of CIN in patients with CKD. Apart from intra-aortic balloon pump use, predictors of CIN in patients without CKD were the same as mentioned, plus older age and type of contrast media. Regardless of baseline renal function, CIN correlated with longer in-hospital stay and higher rates of in-hospital complications and 1-year mortality compared with patients without CIN. By multivariate analysis, CIN was 1 of the most powerful predictors of 1-year mortality in patients with preexisting CKD (odds ratio 2.37, 95% confidence interval 1.63 to 3.44) or preserved eGFR (odds ratio 1.78; 95% confidence interval 1.22 to 2.60). Thus, regardless of the presence of CKD, baseline characteristics and periprocedural hemodynamic parameters predict CIN, and this complication is associated with worse in-hospital and 1-year outcomes. 相似文献
5.
Echols MR Mahaffey KW Banerjee A Pieper KS Stebbins A Lansky A Cohen MG Velazquez E Santos R Newby LK Gurfinkel EP Biasucci L Ferguson JJ Califf RM 《The American journal of cardiology》2007,99(3):315-321
Management and outcomes of patients with acute coronary syndromes (ACSs) may vary according to patient race and ethnicity. To assess racial differences in presentation and outcome in high-risk North American patients with non-ST-segment elevation (NSTE) ACS, we analyzed baseline racial/ethnic differences and all-cause death or nonfatal myocardial infarction (MI) in 6,077 white, 586 African-American, and 344 Hispanic patients through 30-day, 6-month, and 1-year follow-up. Frequencies of hypertension were 66% for whites, 83% for African-Americans, and 78% for Hispanics (overall p <0.001). Use of angiography was similar across groups. Use of percutaneous coronary intervention (46% for whites, 41% for African-Americans, and 45% for Hispanics, overall p = 0.046) and coronary artery bypass grafting (20% for whites, 16% for African-Americans, and 22% for Hispanics, overall p = 0.044) differed. African-American patients had significantly fewer diseased vessels compared with white patients (p = 0.0001). Thirty-day death or MI was 14% for whites, 10% for African-Americans, and 14% for Hispanics (overall p = 0.034). After adjustment for baseline variables, African-American patients had lower 30-day death or MI compared with white patients (odds ratio 0.73, 95% confidence interval 0.55 to 0.98). There were no differences in 6-month death or MI across racial/ethnic groups. In conclusion, baseline clinical characteristics differed across North American racial/ethnic groups in the SYNERGY trial. African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients. 相似文献
6.
7.
Lansky A Goto K Fahy M Cristea E Mehran R Stone GW Feit F Ohman EM Alexander KP White HD Bertrand ME Desmet W Hamon M 《Circulation》2011,123(15):e410-e411
8.
Kenichi Tsujita MD PhD Akiko Maehara MD Gary S. Mintz MD Hiroshi Doi MD PhD Takashi Kubo MD PhD Celia Castellanos MD Jian Liu MD Junqing Yang MD Carlos Oviedo MD Theresa Franklin-Bond MS PA Neil Dasgupta MA Sinan Biro BS Lokesh Dani BA George D. Dangas MD PhD Roxana Mehran MD Ajay J. Kirtane MD Alexandra J. Lansky MD Edward M. Kreps MD Michael B. Collins MD Gregg W. Stone MD Jeffrey W. Moses MD Martin B. Leon MD 《The American journal of cardiology》2008,102(12):1608-1613
9.
Nikolsky E Aymong ED Halkin A Grines CL Cox DA Garcia E Mehran R Tcheng JE Griffin JJ Guagliumi G Stuckey T Turco M Cohen DA Negoita M Lansky AJ Stone GW 《Journal of the American College of Cardiology》2004,44(3):547-553
OBJECTIVES: We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). BACKGROUND: The prognostic importance of anemia on primary PCI outcomes is unknown. METHODS: In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit <39% for men and <36% for women). RESULTS: Anemia was present in 260 (12.8%) of 2,027 randomized patients with baseline laboratory values. Patients with versus without baseline anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001), and had a prolonged (median 4.1 vs. 3.5 days, p < 0.0001) and more expensive (median costs $12,434 vs. $11,603, p = 0.002) index hospitalization. Patients with versus without anemia had strikingly higher mortality during hospitalization (4.6% vs. 1.1%, p = 0.0003), at 30 days (5.8% vs. 1.5%, p < 0.0001), and at 1 year (9.4% vs. 3.5%, p < 0.0001). The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p = 0.005) and at 1 year (2.1% vs. 0.4%, p = 0.0007) were also significantly higher in patients with anemia. By multivariate analysis, anemia was an independent predictor of in-hospital mortality (hazard ratio, 3.26; p = 0.048) and one-year mortality (hazard ratio, 2.38; p = 0.016). CONCLUSIONS: Anemia at baseline in patients with AMI undergoing primary PCI is common, and is strongly associated with adverse outcomes and increased mortality. 相似文献
10.